DATABASE ANALYSIS ON PATIENTS USING IMMUNOBIOLOGICAL DRUGS IN A BRAZILIAN PRIVATE HEALTH CARE PLAN- A REAL WORLD DATA ANALYSIS
Author(s)
Reis HP1, Viana Ad1, Magalhães Dd1, Alcantara AC1, Sartori DP1, Vieira JB1, Ferreira J2, Rodrigues EX1, Filho NG1
1Unimed Fortaleza, Fortaleza, Brazil, 2UFC, Fortaleza, Brazil
OBJECTIVES Patients’ profile undergoing intravenous immunobiological treatment is very limited This study aimed to describe this information from the perspective of a Brazilian health plan, located in Fortaleza METHODS This was a cross sectional study with data obtained from the HMO database as presented by Reis H et al at ISPOR 18th Annual Meeting. Eligible criteria for data analysis were patients being treated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) or Crohn’s disease (CD) who have received at least one dose of immunobiological drug between March/2012 and October/2013. Data was stratified by indication (RA, AS, PsA and CD), patient weight and treatment profile (naïve versus non-naïve patients). RESULTS A total of 118 patients had been analyzed, with an average age of 51 years, and 66.9% (n = 79) of them being women. RA (n = 53, 44,9%) and AS (n = 49, 41,5%) were the most prevalent diseases being treated, followed by PsA (n = 13, 11%) and CD (n = 3, 2,5%). The average weight of patients varied according to the disease being treated: 67 kg for RA and CD, and 70 kg for AS and PsA. It was observed that 65.5% patients were naïve to immunobiological drug, of which 73% initiated treatment with an anti-TNFa, being infliximab the most commonly prescribed one (85.2%). As for patients who had already been previously treated, golimumab and abatacept were the most commonly prescribed drugs (23%), whereas 48.7% out of total were receiving the third immunobiogical drug and 35.9% were receiving the second one. CONCLUSIONS The knowledge of patients profile and treatment information is the basis for any planning strategy in an HMO. Associated with costs, this data is crucial in supporting HMO board decisions on best treatment alternatives and so optimize the provided care.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PSY113
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Hospital and Clinical Practices
Disease
Systemic Disorders/Conditions